- Pink Sheet
Glaxo Opts For Solo Navigation To Boost Control In Consumer Health Market
After announcing the $13bn acquisition of Novartis' 36.5% share of their JV, GSK said its Horlicks nutritional beverage line and its consumer health subsidiary in India, the source of most Horlicks sales, are potential divestments. The firm also will consider selling other consumer health nutrition products.
GlaxoSmithKline PLC brings more certainty to its consumer health business plans, potentially including shedding lagging brands and product lines, by acquiring full control of the OTC drug and nutritional products joint venture it has operated with Novartis AG.
After announcing the £9.2bn ($13bn) acquisition of Novartis' 36
